Accelerating Cannabis Innovation
iCAN INCUBATE identifies and accelerates innovative startups and ideas and creates synergies between them and the global cannabis ecosystem.
We are building a portfolio of diversified investments focused on cannabis pharmaceutical formulations, medical devices, wellness products, AgTech, and other innovative technologies.
About iCAN Incubate
iCAN Incubate offers the guidance and support needed to successfully develop, produce, and market your product.
iCAN Incubate is headquartered in Israel, a leading global center of cannabis research and innovation.
What Do We Do?
iCAN Incubate helps startups and researchers build business models that are scalable and repeatable. By leveraging our deep well of industry know-how and a select group of experts from sectors across the cannabis industry, iCAN Incubate knows what it takes to accelerate and bring new and innovative products to market.
Know your Markets
Develop your Business
Build your Product
Find your Capital
Not all incubators are created equal. At iCAN, our unique panel of advisors, consultants, and strategic partners work in partnership with budding entrepreneurs and innovative researchers to develop the best model for each venture.
iCAN See is the first-mover in incorporating cannabis into ocular health, to address the need for more effective, less harmful ocular treatments. Our distinguished scientific advisory board includes experts from the fields of ophthalmology, clinical research, and biotechnology, who ensure the clinical validity of iCANsee ocular cannabis products, testing the quality and efficacy of each formulation prior to market.
With renewed research interest in LSD, MDMA, Ketamine, and psilocybin, and a growing normalization after decades of stigma, psychedelics are the next therapeutic frontier. The PsyTech conference was created by the team behind CannaTech, the premier innovation conference for the cannabis industry. Leveraging years of experience building a global cannabis ecosystem, PsyTech is poised to elevate the psychedelics conversation, foster normalization, and accelerate innovation.